Evidence map›Paper›PMID 41053498›Full record

Observational studyAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2026

Early SGLT2i Therapy Facilitates In-Hospital ARNI Introduction Improving 6-Month Systolic Function in Patients with HFrEF.

Andrea D'Amato, Silvia Prosperi, Federico Ferranti, Claudia Cestiè, Vincenzo Myftari, Rosanna Germanò, Camilla Segato, Matteo Aulicino, Stefanie Marek-Iannucci, Giovanna Manzi and 9 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Andrea D'Amato *Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Silvia Prosperi *Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Federico FerrantiDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Claudia CestièDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Vincenzo MyftariDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Rosanna GermanòDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Camilla SegatoDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Matteo AulicinoDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Stefanie Marek-IannucciDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Giovanna ManziDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Domenico FilomenaDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Marco Valerio MarianiDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Lucia Ilaria BirtoloDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Silvia PapaDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Massimo ManconeDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Viviana MaestriniDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Roberto BadagliaccaDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Carmine Dario VizzaDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Paolo SeverinoDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy. paolo.severino@uniroma1.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHeart failure with reduced ejection fraction (HFrEF) represents a complex clinical syndrome requiring the timely initiation of disease-modifying therapies. However, the optimal timing for introducing these therapies in the hospital setting remains an area of investigation. This study aims to evaluate whether the early in-hospital initiation of sodium-glucose co-transporter 2 inhibitors (SGLT2i) facilitates the introduction of angiotensin receptor-neprilysin inhibitors (ARNI) during hospitalization and whether this strategy is associated with improved left ventricular systolic function at 6-month follow-up.

methodsIn this prospective, observational, single-centre study, consecutive patients with HFrEF were enrolled and divided into two groups on the basis of the timing of SGLT2i initiation: Group 1 (in-hospital) and Group 2 (post-discharge). The differences in terms of ARNI introduction within hospitalization were evaluated in the two groups. Changes in echocardiographic parameters (left ventricular ejection fraction [LVEF], left ventricular end-diastolic volume [LVEDV], left ventricular end-systolic volume [LVESV], E/e' ratio) at 6-month follow up have been compared among patients treated with ARNI+SGLT2i and SGLT2i alone.

resultsA total of 285 patients were enrolled, 151 for G1 and 134 for G2. Early in-hospital use of SGLT2i was an independent predictor of ARNI initiation before discharge (odds ratio, OR: 3.31; 95% confidence intervals, CI 1.87-5.84; p < 0.001). Among the 89 patients of G1 who completed 6 months of follow-up, early in-hospital therapy with SGLT2i and ARNI represents an independent significant predictor of LVEF > 10% improvement, compared with those treated with SGLT2i alone (OR: 5.353; 95% CI 1.504-12.070; p < 0.003).

conclusionsEarly in-hospital initiation of SGLT2i in patients with HFrEF is associated with a higher likelihood of in-hospital ARNI introduction and with significant improvements in left ventricular systolic function at 6-month follow-up.

Indexed as

Angiotensin Receptor AntagonistsHeart FailureSodium-Glucose Transporter 2 InhibitorsAgedEchocardiographyFemaleHospitalizationHumansMaleMiddle AgedProspective StudiesStroke VolumeSystoleVentricular Function, LeftAngiotensin Receptor AntagonistsSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID41053498
PMCPMC12920402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.